Close
Accuracy Plus Medical Laboratory (APML) is proud to announce a groundbreaking collaboration with IMBdx (In My Blood Diagnostics), a globally recognized leader in liquid biopsy and cancer diagnostics. This strategic alliance brings state-of-the-art ctDNA-based testing technologies directly to the UAE.
What This Means for You:
Access to cutting-edge diagnostics: Now offering innovative tests such as AlphaLiquid®️100, which enables tumor profiling, recurrence monitoring, and detection of minimal residual disease via a simple blood draw.
Broader cancer detection capabilities:
Through the CancerFind™️ multi-cancer early detection assay, our collaboration expands the ability to detect a range of cancers with high accuracy and convenience.
Enhanced precision medicine: Clinicians gain access to critical genomic insights to guide personalized treatment strategies and monitor therapy effectiveness.
Patients and healthcare providers in the UAE benefit from globally advanced molecular diagnostics that were previously only available internationally.
Non-invasive, accurate testing supports quicker diagnoses, earlier interventions, and better patient care pathways.
IMBdx is a pioneer in liquid biopsy innovation, with global recognition for its AlphaLiquid platforms and CancerFind™️ technology. They are KOSDAQ-listed and accredited by top international bodies (e.g., CAP, ISO 13485), underscoring their commitment to precision, quality, and innovation.
By integrating IMBdx’s advanced testing solutions, APML reaffirms its commitment to delivering world-class diagnostics and empowering healthcare professionals with the tools they need for more informed, impactful cancer care.
At Accuracy Plus, we create a scientific, all-inclusive, and value-adding diagnostic culture of excellent, timely test results conforming to world-class testing standards and benchmarks for swifter and better disease detection.
© COPYRIGHT 2025 -ACCURACY PLUS - ALL RIGHTS RESERVED
